CureVac NV (5CV) - Total Liabilities
Based on the latest financial reports, CureVac NV (5CV) has total liabilities worth €267.39 Million EUR (≈ $312.61 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore CureVac NV annual equity growth to track the company's year-over-year net asset growth rate.
CureVac NV - Total Liabilities Trend (2018–2024)
This chart illustrates how CureVac NV's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of CureVac NV to measure how efficiently the company converts operating cash flow to free cash.
CureVac NV Competitors by Total Liabilities
The table below lists competitors of CureVac NV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Apacer Technology Inc
TW:8271
|
Taiwan | NT$2.55 Billion |
|
Whirlpool China Co Ltd
SHG:600983
|
China | CN¥2.84 Billion |
|
Neurones
PA:NRO
|
France | €284.16 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥580.21 Million |
|
Sana Biotechnology Inc
NASDAQ:SANA
|
USA | $254.35 Million |
|
Nsfocus Information Technology Co Ltd
SHE:300369
|
China | CN¥1.98 Billion |
|
Guangzhou Pearl River Piano Group Co Ltd
SHE:002678
|
China | CN¥594.22 Million |
|
Cementos Pacasmayo SAA ADR
NYSE:CPAC
|
USA | $1.86 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down CureVac NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CureVac NV stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CureVac NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CureVac NV (2018–2024)
The table below shows the annual total liabilities of CureVac NV from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €106.22 Million ≈ $124.18 Million |
-60.85% |
| 2023-12-31 | €271.31 Million ≈ $317.19 Million |
-17.09% |
| 2022-12-31 | €327.22 Million ≈ $382.55 Million |
-30.34% |
| 2021-12-31 | €469.77 Million ≈ $549.21 Million |
-41.28% |
| 2020-12-31 | €800.01 Million ≈ $935.29 Million |
+361.31% |
| 2019-12-31 | €173.42 Million ≈ $202.75 Million |
+85.33% |
| 2018-12-31 | €93.58 Million ≈ $109.40 Million |
-- |
About CureVac NV
As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRN… Read more